Lista, AGD, Romero-Laorden, N, Gajate, P, Orta-Ruiz, A, Jiménez, JGD, Miranda, MJ, Estévez, SV, Molins, C, Pernaut, C, Cordero, MG, Fernández, O, Sánchez, JG, Maeso, IG, Blazquez, PR, Reig, O, Maroto-Rey, P, Martín, A, Ramirez, I, Puente, J. Effectiveness and safety of first-line atezolizumab in locally advanced or metastatic urothelial cancer: The IMFLAME study.. JOURNAL OF CLINICAL ONCOLOGY. 2025; 43(5_SUPPL)DOI:10.1200/JCO.2025.43.5_suppl.720. PMID:. IF:41.900(Q1/1D).

Cortellini, A, Brunetti, L, Di Fazio, GR, Garbo, E, Pinato, DJ, Naidoo, J, Katz, A, Loza, M, Neal, JW, Genova, C, Gettinger, S, Kim, SY, Jayakrishnan, R, El Zarif, T, Russano, M, Pecci, F, Di Federico, A, Awad, M, Alessi, J, Montrone, M, Owen, DH, Signorelli, D, Fidler, MJ, Li, MJ, Camerini, A, De Giglio, A, Young, L, Vincenzi, B, Metro, G, Passiglia, F, Yendamuri, S, Guida, A, Ghidini, M, Awosika, NO, Napolitano, A, Fulgenzi, CAM, Grisanti, S, Grossi, F, D'Incecco, A, Josephides, E, Van Hemelrijck, M, Russo, A, Gelibter, A, Spinelli, G, Verrico, M, Tomasik, B, Giusti, R, Newsom-Davis, T, Bria, E, Sebastian, M, Rost, M, Forster, M, Mukherjee, U, Landi, L, Mazzoni, F, Aujayeb, A, Dupont, M, Curioni-Fontecedro, A, Chiari, R, Pantano, F, Morabito, A, Leonetti, A, Friedlaender, A, Addeo, A, Zoratto, F, De Tursi, M, Cantini, L, Roca, E, Mountzios, G, Della Gravara, L, Kalvapudi, S, Inno, A, Bironzo, P, Barros, RD, O'Reilly, D, Bell, J, Karapanagiotou, E, Monnet, I, Baena, J, Macerelli, M, Majem, M, Agustoni, F, Cortinovis, DL, Tonini, G, Minuti, G, Bennati, C, Mezquita, L, Gorría, T, Servetto, A, Beninato, T, Lo Russo, G, Rogado, J, Moliner, L, Biello, F, Nana, FA, Dingemans, AM, Aerts, JGJ, Ferrara, R, Torri, V, Abu Hejleh, T, Takada, K, Naqash, AR, Garassino, M, Peters, S, Wakelee, H, Nassar, AH, Ricciuti, B. Determinants of 5-year survival in patients with advanced NSCLC with PD-L1=50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry. Journal for ImmunoTherapy of Cancer. 2025; 13(2)DOI:10.1136/jitc-2024-010674. PMID:39904562. IF:10.600(Q1/1D).

Castro, CG, López, S, Garcia-Alfonso, P, Martinez, CF, González, BD, Ortiz, MJ, Paez, D, Lopez, CM, La Casta, A, Sosa, MM, Valera, JS, Ghanem, I, Vidal-Tocino, R, Santos, C, Garcia-Benito, C, Jimenez, E, Guillot, M, Verdaguer, H, Montes, AFF. A cross-sectional analysis from a real-world cohort of patients with microsatellite instability colorectal cancer (MSI-CRC) with metastatic disease from the Spanish RETUD registry.. JOURNAL OF CLINICAL ONCOLOGY. 2025; 43(4_SUPPL)DOI:10.1200/JCO.2025.43.4_suppl.178. PMID:. IF:41.900(Q1/1D).

Martelli, V, Barrull, JV, Fernandez-Rodríguez, C, Gibert, J, Moreno, A, Louhamane, A, Linares-Aceituno, J, Garcia-Alfonso, P, Paez, D, Alonso, V, Espana, MAG, Santos, C, Duran, G, Elez, E, Paricio, BB, Tabernero, J, Salazar, R, Aranda, E, Toledo, RA, Montagut, CO. Plasma shallow whole-genome sequencing profiling in patients with RASWT metastatic colorectal cancer (mCRC) undergoing first-line anti-EGFR therapy.. JOURNAL OF CLINICAL ONCOLOGY. 2025; 43(4_SUPPL)DOI:10.1200/JCO.2025.43.4_suppl.214. PMID:. IF:41.900(Q1/1D).

Montes, AFF, Lopez, CM, Lopez, S, Martinez, CF, Paez, D, Gonzalez, BD, Espana, MAG, Garcia-Benito, C, Vidal-Tocino, R, Sosa, MM, Valera, JS, Garcia-Alfonso, P, Ghanem, I, La Casta, A, Gallego, J, Verdaguer, H, Santos, C, Jimenez, E, Gravalos, C. A cross-sectional analysis from a real-world cohort of patients with microsatellite instability colorectal cancer (MSI-CRC) with localized disease from the Spanish RETUD registry.. JOURNAL OF CLINICAL ONCOLOGY. 2025; 43(4_SUPPL)DOI:10.1200/JCO.2025.43.4_suppl.173. PMID:. IF:41.900(Q1/1D).

Olmos, VP, Pollán, M, de Larrea-Baz, NF, Fernández-Morata, J, Ruiz-Moreno, E, García-Pérez, J, Castelló, A, Sierra, MA, Lucas, P, Alonso-Ledesma, I, Stradella, A, Cantos, B, Cajal, TRY, Santisteban, M, Seguí, MA, Bertrán, AS, Granja, M, Camps-Herrero, J, Recalde, S, Mendez, M, Verges, NC, Pérez-Gómez, B, Pastor-Barriuso, R, Lope, V. Determinants of Adherence to World Cancer Research Fund/American Institute for Cancer Research Recommendations in Women with Breast Cancer. Cancers. 2025; 17(4)DOI:10.3390/cancers17040708. PMID:40002301. IF:4.400(Q2/3D).

Flix-Valle, A, Medina, JC, Souto-Sampera, A, Arizu-Onassis, A, Juan-Linares, E, Serra-Blasco, M, Ciria-Suárez, L, Feixas, G, Ochoa-Arnedo, C. Therapeutic alliance in a stepped digital psychosocial intervention for breast cancer patients: findings from a multicentre randomised controlled trial. BJPsych Open. 2025; 11(1)DOI:10.1192/bjo.2024.844. PMID:39865983. IF:3.500(Q1/3D).

Martin-Broto, J, Diaz-Beveridge, R, Moura, D, Ramos, R, Martinez-Trufero, J, Carrasco, I, Sebio, A, Gonzalez-Billalabeitia, E, Gutierrez, A, Fernandez-Jara, J, Hernandez-Vargas, L, Cruz, J, Valverde, C, Hindi, N. Phase Ib Study for the Combination of Doxorubicin, Dacarbazine, and Nivolumab as the Upfront Treatment in Patients With Advanced Leiomyosarcoma: A Study by the Spanish Sarcoma Group (GEIS). JOURNAL OF CLINICAL ONCOLOGY. 2025; 43(3)DOI:10.1200/JCO.24.00358. PMID:39356980. IF:41.900(Q1/1D).

Martinez-Recio, S, Molina-Pérez, MA, Muñoz-Couselo, E, Sevillano-Tripero, AR, Aya, F, Arance, A, Orrillo, M, Martin-Liberal, J, Fernandez-Morales, L, Lesta, R, Quindós-Varela, M, Nieva, M, Vidal, J, Martinez-Perez, D, Barba, A, Majem, M. Adjuvant Immunotherapy After Resected Melanoma: Survival Outcomes, Prognostic Factors and Patterns of Relapse. Cancers. 2025; 17(1)DOI:10.3390/cancers17010143. PMID:39796770. IF:4.400(Q2/3D).

Sebio, A, Berger, C, Tabone, MD, Fernandez, N, Tardy, F, Grootenhuis, M, Palmerini, E, Gaspar, N, van de Sande, M, Haveman, LM. Quality of Life and Patient-Reported Outcomes in Patients With Osteosarcoma: A Systematic Review. EUROPEAN JOURNAL OF CANCER CARE. 2025; 2025(1)DOI:10.1155/ecc/5802523. PMID:. IF:1.900(Q2/4D).

Piedra, A, Martínez-Recio, S, Hernández, A, Morán, T, Arriola, E, Recuero-Borau, J, Cobo, M, Cordeiro, P, Mosquera, J, Fernández, M, García-Campelo, R, Calles, A, Alvarez, R, Zapata-García, M, Isla, D, Callejo, A, Iranzo, P, Serra-López, J, Barba, A, Sullivan, I, Felip, E, Majem, M. First-line pembrolizumab in patients with advanced non-small cell lung cancer and high PD-L1 expression: real-world data from a Spanish multicenter study. Frontiers in Oncology. 2024; 14DOI:10.3389/fonc.2024.1510278. PMID:39741981. IF:3.300(Q2/4D).

Soria Rivas A, Escobar Álvarez Y, Blasco Cordellat A, Majem Tarruella M, Molina Mata K, Motilla de la Cámara M, Del Mar Muñoz Sánchez M, Zafra Poves M, Beato Zambrano C, Cabezón Gutierrez L. SEOM clinical guidelines for cancer anorexia-cachexia syndrome (2023).. Clinical & Translational Oncology. 2024; 26(11)DOI:10.1007/s12094-024-03502-8. PMID:38822976. IF:(Q/D).

Volta-Duran, E, Sanchez, JM, Hector-Lopez-Laguna, Parlade, E, Sanchez-Garcia, L, Sanchez-Chardi, A, de Marco, A, Unzueta, U, Vazquez, E, Villaverde, A. The spectrum of building block conformers sustains the biophysical properties of clinically-oriented self-assembling protein nanoparticles. Science China-Materials. 2022; 65(6)DOI:10.1007/s40843-021-1914-0. PMID:. IF:8.100(Q1/3D).

Parlade, E, Volta-Duran, E, Cano-Garrido, O, Sanchez, JM, Unzueta, U, Lopez-Laguna, H, Serna, N, Cano, M, Rodriguez-Mariscal, M, Vazquez, E, Villaverde, A. An In Silico Methodology That Facilitates Decision Making in the Engineering of Nanoscale Protein Materials. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2022; 23(9)DOI:10.3390/ijms23094958. PMID:35563346. IF:5.600(Q1/3D).

Barguilla, I, Unzueta, U, Carratala, JV, Cano-Garrido, O, Villaverde, A, Hernandez, A, Ferrer-Miralles, N. Toxicity Profiling of Bacterial Inclusion Bodies in Human Caco-2 Cells. Frontiers in Bioengineering and Biotechnology. 2022; 10DOI:10.3389/fbioe.2022.842256. PMID:35573225. IF:5.700(Q1/3D).

Sanchez, JM, Carratala, JV, Serna, N, Unzueta, U, Nolan, V, Sanchez-Chardi, A, Volta-Duran, E, Lopez-Laguna, H, Ferrer-Miralles, N, Villaverde, A, Vazquez, E. The Poly-Histidine Tag H6 Mediates Structural and Functional Properties of Disintegrating, Protein-Releasing Inclusion Bodies. Pharmaceutics. 2022; 14(3)DOI:10.3390/pharmaceutics14030602. PMID:35335976. IF:5.400(Q1/2D).

López-Laguna H, Voltà-Durán E, Parladé E, Villaverde A, Vázquez E, Unzueta U. Insights on the emerging biotechnology of histidine-rich peptides. BIOTECHNOLOGY ADVANCES. 2022; 54DOI:10.1016/j.biotechadv.2021.107817. PMID:34418503. IF:16.000(Q1/1D).

Serna, N, Carratala, JV, Conchillo-Sole, O, Martinez-Torro, C, Unzueta, U, Mangues, R, Ferrer-Miralles, N, Daura, X, Vazquez, E, Villaverde, A. Antibacterial Activity of T22, a Specific Peptidic Ligand of the Tumoral Marker CXCR4. Pharmaceutics. 2021; 13(11)DOI:10.3390/pharmaceutics13111922. PMID:34834337. IF:6.525(Q1/2D).

Lopez-Laguna, H, Sanchez, JM, Carratala, JV, Rojas-Pena, M, Sanchez-Garcia, L, Parlade, E, Sanchez-Chardi, A, Volta-Duran, E, Serna, N, Cano-Garrido, O, Flores, S, Ferrer-Miralles, N, Nolan, V, de Marco, A, Roher, N, Unzueta, U, Vazquez, E, Villaverde, A. Biofabrication of functional protein nanoparticles through simple His-tag engineering. ACS Sustainable Chemistry & Engineering. 2021; 9(36)DOI:10.1021/acssuschemeng.1c04256. PMID:34603855. IF:9.224(Q1/1D).

Sanchez-Garcia, L, Volta-Duran, E, Parlade, E, Mazzega, E, Sanchez-Chardi, A, Serna, N, Lopez-Laguna, H, Mitstorfer, M, Unzueta, U, Vazquez, E, Villaverde, A, de Marco, A. Self-Assembled Nanobodies as Selectively Targeted, Nanostructured, and Multivalent Materials. ACS Applied Materials & Interfaces. 2021; 13(25)DOI:10.1021/acsami.1c08092. PMID:34129336. IF:10.383(Q1/2D).